je.st
news
Tag: therapeutics
Highland Therapeutics Announces Initiation Of Second Pivotal Trial Of HLD-200 In Pediatric ADHD Patients
2015-09-02 07:45:41| drugdiscoveryonline News Articles
Highland Therapeutics Inc. (“Highland”) announced recently that its wholly owned subsidiary, Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), has dosed the first patient in the second of two pivotal studies of HLD-200
Tags: trial
patients
adhd
announces
RetroSense Therapeutics' Lead Gene Therapy Candidate Gets FDA Clearance To Proceed To First-In-Human Clinical Trials
2015-09-02 07:40:59| drugdiscoveryonline News Articles
RetroSense Therapeutics LLC, a privately-held biopharmaceutical company, recently announced the Company’s Investigational New Drug (IND) application for RST-001 received clearance from the United States Food and Drug Administration (FDA)
Tags: lead
clinical
therapy
candidate
BIO Issues Statement on Acorda Therapeutics patent challenges.
2015-08-28 14:31:07| Industrial Newsroom - All News for Today
In addition to applauding U.S. Patent and Trademark Office's decision to reject challenges to 2 patents held by Acorda Therapeutics, BIO President and CEO Jim Greenwood stated that it remained critical for Congress and PTO to continue efforts to reform Inter Partes Review (IPR) process. This was, according to Greenwood, to ensure it operates in a balanced manner. Greenwood went on to cite 10 additional petitions submitted by Mr. Bass in the same month, an improper use of IPR system.
Tags: issues
statement
bio
challenges
Global Blood Therapeutics latest biotech to double in debut
2015-08-13 03:48:28| Biotech - Topix.net
Blood disorder drug developer Global Blood Therapeutics' shares more than doubled Wednesday as the company became the latest biotechnology company to get a powerful response from investors in its stock market debut. Global Blood Therapeutics Inc. says its treatment for sickle cell disease might stop red blood cells from becoming misshapen, treating the disease rather than its symptoms.
Tags: latest
global
double
blood
Maxim Group Cuts Cytori Therapeutics Price Target to $5.00
2015-08-09 03:47:14| Biotech - Topix.net
Separately, Roth Capital restated a "buy" rating and issued a $6.00 target price on shares of Cytori Therapeutics in a research note on Tuesday, June 16th. Shares of Cytori Therapeutics traded up 2.5122% during midday trading on Friday, reaching $0.4203.
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] next »